SMC021

Summary

Smc021 (CHEMBL3545415) is a phase-3 clinical-stage unknown; indicated across 4 conditions including osteoporosis and osteoarthritis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545415
Name	SMC021
Type	Unknown
Max phase	3

Also known as: Smc021, SMC021

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoporosis	3	MONDO:0005298	EFO:0003882
osteoarthritis	3	MONDO:0005178	MONDO:0005178
postmenopausal osteoporosis	1	MONDO:0008159	EFO:0003854

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00486434	PHASE3	COMPLETED	Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis
NCT00525798	PHASE3	COMPLETED	A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D
NCT00421590	PHASE2	COMPLETED	Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).